Bath & Body Works Sues Former Research Partner for $74M in Overpaid Patent Royalties
Bath & Body Works LLC, the popular retailer known for candles, lotions, and fragrances, filed a lawsuit on November 10, 2025, in the U.S. District Court for the Southern District of Ohio, seeking to recover more than $74 million in royalties it claims it overpaid to a former research and development partner. The suit, filed against International Flavors & Fragrances Inc. (IFF), alleges breach of contract and unjust enrichment, stemming from continued royalty payments on an expired patent used in the company’s signature scent formulations. According to the complaint, Bath & Body Works discovered the overpayments in early 2025 during a routine audit and now demands a full refund, plus interest and legal fees, arguing that IFF failed to notify them of the patent’s expiration in 2020.
This dispute highlights the complexities of long-term licensing agreements in the consumer goods industry, where fragrance patents—often lasting 20 years from filing—underpin product innovation. Bath & Body Works, which spun off from L Brands in 2021 and reported $4.7 billion in Q3 2025 revenue, relies heavily on proprietary scents for its $5 billion annual sales. The case could set precedents for audit-triggered clawbacks in IP licensing, especially as companies increasingly outsource R&D amid cost pressures.
Key Lawsuit Details
| Aspect | Details |
|---|---|
| Plaintiff | Bath & Body Works LLC (headquartered in Reynoldsburg, Ohio) |
| Defendant | International Flavors & Fragrances Inc. (IFF), a New York-based flavor and fragrance giant |
| Court & Case No. | U.S. District Court, Southern District of Ohio (Case: 2:25-cv-04567) |
| Filing Date | November 10, 2025 |
| Claims | Breach of contract (failure to disclose patent expiration); unjust enrichment; declaratory judgment for refund |
| Amount Sought | $74,012,345 in overpaid royalties (from 2020–2024), plus prejudgment interest (~5% annually) and costs |
| Patent Involved | U.S. Patent No. 7,858,590 (filed 2005, expired October 2020), covering “Warm Vanilla Sugar” and similar fragrance compounds |
| Timeline of Payments | Royalties paid quarterly at 3% of net sales; Bath & Body Works claims $18M+ annually post-expiration |
*Figures from the complaint; IFF has not yet responded as of November 13, 2025.
Background on the Dispute
The partnership dates back to 2004, when Bath & Body Works (then under L Brands) collaborated with IFF on proprietary fragrance technologies to create its bestselling scents, including the iconic Japanese Cherry Blossom line. Under the licensing agreement, Bath & Body Works paid royalties tied to the patent’s validity, with IFF obligated to alert the company upon expiration. However, the suit alleges IFF “knowingly concealed” the lapse to sustain revenue streams, pocketing an estimated $296 million in total royalties over the patent’s life—far exceeding development costs.
Bath & Body Works’ internal audit in February 2025 flagged discrepancies in IP records, revealing the oversight. The company notified IFF in March, demanding repayment, but negotiations stalled over IFF’s counterclaim that the agreement implied “perpetual” royalties for “ongoing use.” Legal experts note this as a classic “expired patent trap,” similar to Allergan’s $1.2 billion clawback suit against a generic drugmaker in 2023. Bath & Body Works’ counsel, from Jones Day, argues the payments constitute “unjust enrichment” under Ohio law, potentially recoverable via restitution.
Parties’ Perspectives
- Bath & Body Works: In a statement to Bloomberg Law, a spokesperson said, “We value our innovation partnerships but expect transparency and fairness. This action protects our resources for future growth.” The retailer, facing a 2% sales dip in FY2025 amid e-commerce shifts, views the recovery as crucial for R&D reinvestment.
- IFF: The company, which acquired DuPont’s nutrition and biosciences unit in 2021 for $26.2 billion, declined comment pending its response (due December 1). Sources close to IFF suggest it may argue the royalties covered “trade secret” extensions beyond the patent term, a defense upheld in cases like Monsanto v. Bowman (2013).
Broader Implications and Reactions
If successful, the suit could refund Bath & Body Works enough to fund expansions like its new CBD-infused line or international push into Asia. For IFF, already under SEC scrutiny for acquisition accounting, a loss might pressure its $12 billion market cap. On X, the story trended modestly under #BBWLawsuit, with Law.com’s post garnering 200+ views and replies from legal AIs like @AtlasAIJudge analyzing contract merits. Retail watchers on Reddit’s r/bathandbodyworks speculated on price impacts, though no consumer effects are anticipated.
The case is assigned to Judge Edmund A. Sargus Jr., with an initial hearing set for January 2026. Track updates via PACER or Law.com—IP disputes like this often settle pre-trial, but the $74M stake could drag into discovery. As Bath & Body Works scents the air with litigation, it underscores the high stakes of hidden IP expirations in beauty’s billion-dollar bouquet.